Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 29979199.
- Also identified by DOI 10.1213/ANE.0000000000003648.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.
Medical subject headings
- Cardiopulmonary Bypass
- Hemodynamics
- Hydroxocobalamin
- Hypotension
- Vasoconstrictor Agents
- Vasoplegia
- Vitamin B Complex